Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Published:2018-03-29 Issue:12 Volume:24 Page:2758-2770
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

McCoach Caroline E.,Blakely Collin M.,Banks Kimberly C.,Levy Benjamin,Chue Ben M.,Raymond Victoria M.^ORCID,Le Anh T.,Lee Christine E.,Diaz Joseph,Waqar Saiama N.,Purcell William T.,Aisner Dara L.,Davies Kurtis D.,Lanman Richard B.^ORCID,Shaw Alice T.,Doebele Robert C.

Funder

University of Colorado Lung Cancer SPORE

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance;JTO Clinical and Research Reports;2024-09

2. Serial Cell-Free DNA Sequencing in ROS1 Fusion–Positive Lung Cancers During Treatment With Entrectinib;JCO Precision Oncology;2024-06

3. NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers;The Journal of Liquid Biopsy;2024-06

4. Spectrum of Resistance Mechanisms to ALK TKIs in NSCLC: Largest Single-Center Experience from India;South Asian Journal of Cancer;2024-05-29

5. Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC;Expert Review of Anticancer Therapy;2024-04-21